Navigation Links
Misonix Reports Nine Months Fiscal 2013 Financial Results
Date:5/9/2013

FARMINGDALE, N.Y., May 9, 2013 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), a surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products worldwide for spine surgery, cranial maxillo – facial surgery, neurosurgery,  wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications, today reported financial results for the nine months and the third quarter of fiscal year 2013, ended March 31, 2013.

Highlights for the quarter and the nine month period include:

  • Revenue for the nine months increased 7% to $11.1 million compared to $10.4 million in the first nine months of 2012. Third quarter revenue decreased 17% to $3.0 million compared to $3.6 million in the third quarter of 2012.
  • BoneScalpel™ revenue increased 55% for the first nine months of 2013; SonicOne revenue increased 83% for the nine months.
  • Excluding revenue from legacy products, BoneScalpel, SonicOne and SonaStar revenue increased 27% for the first nine months of fiscal 2013 to $10.2 million versus the comparable period in 2012.
  • For the nine months, BoneScalpel, SonicOne and SonaStar domestic sales increased 39% to $3.6 million.
  • Bone Scalpel domestic disposables revenue and domestic units sold increased 48% and 44% respectively, over the second quarter fiscal 2013.
  • Royalty income received totaled $1.8 million for the nine months ended March 31, 2013 versus $462,000 for the same period in fiscal 2012.
  • During the quarter, the Company received 2 method-of-use patents related to the BoneScalpel product; and applied for 5 patents, including method-of-use and upgraded technology for the BoneScalpel product.
  • Cash and cash equivalents totaled $6.1 million at March 31, 2013 with no long-term debt.
  •  For the nine months, the Company reported a
    '/>"/>

  • SOURCE Misonix, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Misonix Announces New Distribution Agreement For Denmark
    2. Misonix Reports Financial Results for First Half of Fiscal 2013
    3. Misonix Presents at MicroCapClub Invitational
    4. Misonix Terminates Distribution Agreement With Aesculap
    5. Misonix Reports Strong Revenue Increases for the First Quarter of Fiscal 2013
    6. Misonix Reports Strong Revenue Increases for the Three Months and Full-Year Ended June 30, 2012
    7. Misonix Product Featured At Neurosurgery Congress
    8. Misonix Adds 6 Spine Sales Agencies In The U.S.
    9. Misonix Attends International Meeting On Advanced Spine Techniques (IMAST) - Introduces New Product
    10. Misonix Inks New Distribution Agreement For Croatia And Slovenia
    11. Misonix And Soelim Create New Distribution Alliance For South Korea
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/27/2015)... , July 27, 2015 Research ... the addition of the "Wound Care ... Opportunities: 2015-2020 Analysis And Forecasts" report ... information and evaluation of the global Wound ... manufacturers, segmentation, product offerings, competitive shares, financial ...
    (Date:7/27/2015)...   DocResponse was ranked the most ... peer-reviewed study , "Evaluation of symptom checkers ... in the July issue of The British Medical ... School researchers determined that performance of online symptom ... diagnosis first in standardized patient evaluations more often ...
    (Date:7/27/2015)... -- Syneron Medical Ltd. (NASDAQ: ... in the aesthetic medical device marketplace, announced today that ... Safety (MFDS) regulatory clearance for the PicoWay® picosecond laser. ... orders from its Korean distribution partner, with additional commercial ... quarter 2015. Amit Meridor, Chief Executive Officer ...
    Breaking Medicine Technology:Global Wound Care Markets 2015-2020 - Traditonal, Advanced And Regenerative: Competitors And Opportunities 2Harvard Study Finds DocResponse Most Accurate Medical Symptom Checker/Diagnostics Application 2Harvard Study Finds DocResponse Most Accurate Medical Symptom Checker/Diagnostics Application 3Syneron Receives Korean MFDS Regulatory Clearance for PicoWay Picosecond Laser 2Syneron Receives Korean MFDS Regulatory Clearance for PicoWay Picosecond Laser 3Syneron Receives Korean MFDS Regulatory Clearance for PicoWay Picosecond Laser 4
    ... HORSHAM, Pa. , Jan. 14 Findings ... and safety of STELARA™ (ustekinumab) with etanercept (Enbrel®) in the ... The New England Journal of Medicine.  The results ... STELARA than with etanercept over a 12-week period.  The first-of-its-kind ...
    ... , OSHKOSH, Wis. ... ImproMed, Inc. creators of the Infinity veterinary practice ... services on behalf of veterinarians, announce the integration of VetCentric,s ... the release of v4.5 of Infinity, veterinarians can offer home ...
    Cached Medicine Technology:STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine 2STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine 3STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine 4STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine 5STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine 6STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine 7STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine 8STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine 9VetCentric and ImproMed, Inc.(R) Announce One-Click Home Delivery Integration 2VetCentric and ImproMed, Inc.(R) Announce One-Click Home Delivery Integration 3
    (Date:7/27/2015)... ... July 28, 2015 , ... Almost a year ago, the US ... counseling for persons who are obese and those who are overweight with at least ... mandate will affect any commercial health plan with a program year start after August ...
    (Date:7/27/2015)... ... July 27, 2015 , ... Specific cardiovascular risk factors, ... brain volumes that may be early indicators of Alzheimer’s disease and dementia, according ... that vascular risk factors damage the brain and can result in cognitive impairment,” ...
    (Date:7/27/2015)... ... July 28, 2015 , ... The National ... a 2015 Professional Woman of the Year. Ms. Baum-Lappe is recognized with this ... professional women in the country, spanning virtually every industry and profession, the National ...
    (Date:7/27/2015)... ... July 27, 2015 , ... The FSH Society ... incurable disease, facioscapulohumeral muscular dystrophy (FSHD), today announced the introduction of the first-ever ... care guideline is published today. , This new guideline condenses the results ...
    (Date:7/27/2015)... ... July 27, 2015 , ... Eugene Batelli, D.P.M., F.A.C.F.A.S, just recently ... “The patient is high-end athlete, whose accomplishments include running in 27 triathlons and swimming ... pain, which was diagnosed as tendinitis. I did an ultrasound and found a ...
    Breaking Medicine News(10 mins):Health News:How Digital Therapeutics Can Help Payers Out of Regulatory Fix 2Health News:How Digital Therapeutics Can Help Payers Out of Regulatory Fix 3Health News:RSNA: Specific Cardiovascular Risk Factors May Predict Alzheimer’s Disease 2Health News:RSNA: Specific Cardiovascular Risk Factors May Predict Alzheimer’s Disease 3Health News:NAPW Inducts Gilda Baum-Lappe, Journalist / Correspondent of Hollywood Foreign Press Association Into its VIP Woman of the Year Circle 2Health News:First-Ever FSHD Evidence-based Care Guideline Published by the American Academy of Neurology 2Health News:NJ Top Docs Presents, Dr. Eugene Batelli of Metropolitan Ankle & Foot Care Specialists 2Health News:NJ Top Docs Presents, Dr. Eugene Batelli of Metropolitan Ankle & Foot Care Specialists 3
    ... AMDL, Inc. (NYSE Alternext US: ADL) , a ... its Chairman and CEO Mr. Douglas MacLellan has appeared ... 4, 2009 at 6:40 a.m. ET (3:40 a.m. PT). ... Fox Business News to discuss the Chinese business environment ...
    ... to Advance Understanding and Treatment of Pulmonary Fibrosis ... for Pulmonary Fibrosis (CPF) and the American Thoracic ... pulmonary, critical care and sleep physicians, today announced ... University Medical Center (Columbus, OH) and Harikrishna ...
    ... to share their heart-healthy lifestyle choicesDALLAS, Feb. 4 ... while others are life changing. Heart disease is the ... research shows that eighty percent of cardiac events in ... choices for their hearts, involving diet, exercise and abstinence ...
    ... Invisicare to ChinaLAS VEGAS and PLAINSBORO, N.J., Feb. 4 ... the developers of Invisicare , a ... for topical products, and RHEI Pharmaceuticals NV, a Belgium ... China, today announced they have signed a first option ...
    ... (Nasdaq: CADX ), a biopharmaceutical company focused ... for use in the hospital setting, announced today that ... the company,s corporate overview on Tuesday, February 10, 2009 ... BIO CEO and Investor Conference at the Waldorf Astoria ...
    ... Several big names in professional football and television ... 28 for the Third Annual National Walk for Epilepsy. ... Alan Faneca, and Atlanta Falcons running back Jason Snelling, ... their own teams of friends, relatives and fans. Together ...
    Cached Medicine News:Health News:AMDL Inc.'s Chairman & CEO Mr. Douglas MacLellan Featured on FOX Business News Wednesday, February 4, 2009 2Health News:AMDL Inc.'s Chairman & CEO Mr. Douglas MacLellan Featured on FOX Business News Wednesday, February 4, 2009 3Health News:Coalition for Pulmonary Fibrosis and American Thoracic Society Announce Recipients of 2009-10 Research Awards 2Health News:Coalition for Pulmonary Fibrosis and American Thoracic Society Announce Recipients of 2009-10 Research Awards 3Health News:Coalition for Pulmonary Fibrosis and American Thoracic Society Announce Recipients of 2009-10 Research Awards 4Health News:Go Red For Women(R) Hosts Casting Call to Beat No. 1 Killer of Women With Celebrity Supporter Andie MacDowell 2Health News:Go Red For Women(R) Hosts Casting Call to Beat No. 1 Killer of Women With Celebrity Supporter Andie MacDowell 3Health News:Go Red For Women(R) Hosts Casting Call to Beat No. 1 Killer of Women With Celebrity Supporter Andie MacDowell 4Health News:Skinvisible Signs Dermatology Agreement With RHEI Pharmaceuticals 2Health News:Skinvisible Signs Dermatology Agreement With RHEI Pharmaceuticals 3Health News:Skinvisible Signs Dermatology Agreement With RHEI Pharmaceuticals 4Health News:Video: Celebrities and Professional Athletes Invite the Public to Join them at the Third Annual National Walk for Epilepsy on March 28, in Washington, D.C. 2Health News:Video: Celebrities and Professional Athletes Invite the Public to Join them at the Third Annual National Walk for Epilepsy on March 28, in Washington, D.C. 3
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    Medicine Products: